Citations

Showing 10 of 108083 citations.

Utility of Metagenomic Next-Generation Sequencing in Infective Endocarditis: A Systematic Review
Haddad, Sara F. , Chesdachai, Supavit , Gerberi, Dana , Baddour, Larry M. , Chesdachai, Supavit , Gerberi, Danielle J , Baddour, Larry , Haddad, Sara F , DeSimone, Daniel C.

Mayo Clinic

Antibiotics | December 12, 2022 | Volume: 11 | Issue: 12 | Pages: 1798

10.3390/antibiotics11121798 | PMID 36551455 Get It

Blood cultures have been the gold standard for identifying pathogens in infective endocarditis (IE). Blood culture-negative endocarditis (BCNE), however, occurs in 40% or more of IE cases with the bulk of them due to recent antibiotic exposure prior to obtaining blood cultures. Increasingly, molecular techniques are being used for pathogen identification in cases of BCNE and more recently has included metagenomic next-generation sequencing (mNGS). We therefore performed a literature search on August 31, 2022, that assessed the mNGS in IE and 13 publications were identified and included in a systematic review. Eight (61.5%) of them focused only on IE with mNGS performed on cardiac valve tissue in four studies, plasma in three studies and cardiac implantable electronic devices (CIED) in one study. Gram-positive cocci, including Staphylococcus aureus (n = 31, 8.9%), coagulase-negative staphylococci (n = 61, 17.6%), streptococci (n = 130, 37.5%), and Enterococcus faecalis (n = 23, 6.6%) were the predominant organisms identified by mNGS. Subsequent investigations are needed to further define the utility of mNGS in BCNE and its impact on patient outcomes. Despite some pitfalls, mNGS seems to be of value in pathogen identification in IE cases, particularly in those with BCNE. This study was registered and on the Open Science Framework platform.
Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer’s Disease
Cho, Hyung Joon , Schulz, Philip , Venkataraman, Lalitha , Caselli, Richard J. , Sierks, Michael R. , Schulz, Philip

Mayo Clinic

International Journal of Molecular Sciences | December 12, 2022 | Volume: 23 | Issue: 24 | Pages: 15670

10.3390/ijms232415670 | PMID 36555310 Get It

Blood-based biomarkers are needed for the early diagnosis of Alzheimer’s disease (AD). We analyzed longitudinal human plasma samples from AD and control cases to identify biomarkers for the early diagnosis of AD. Plasma samples were grouped based on clinical diagnosis at the time of collection: AD, mild cognitive impairment (MCI), and pre-symptomatic (preMCI). Samples were analyzed by ELISA using a panel of reagents against nine different AD-related amyloid-β (Aβ), tau, or TDP-43 variants. Receiver operating characteristic (ROC) curves of different biomarker panels for different diagnostic sample groups were determined. Analysis of all of the samples gave a sensitivity of 92% and specificity of 76% for the diagnosis of AD. Early-stage diagnosis of AD, utilizing only the preMCI and MCI samples, identified 88% of AD cases. Using sex-biased biomarker panels, early diagnosis of AD cases improved to 96%. Using the sex-biased panels, we also identified 6 of the 25 control group cases as being at high risk of AD, which is consistent with what is expected given the advanced age of the control cases. Specific AD-associated protein variants are effective blood-based biomarkers for the early diagnosis of AD. Notably, significant differences were observed in biomarker profiles for the early detection of male and female AD cases.
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium
Rodday, Angie Mae , Parsons, Susan K. , Upshaw, Jenica , Friedberg, Jonathan W. , Gallamini, Andrea , Hawkes, Eliza A. , Hodgson, David , Johnson, Peter , Link, Brian K. , Mou, Eric , Evens, Andrew M. , Upshaw, Jenica N , Hawkes, Eliza , Savage, Kerry J , Zinzani, Pier Luigi , Maurer, Matthew , Evens, Andrew M , Link, Brian K , Gallamini, Andrea , Hodgson, David , Johnson, Peter , K Parsons, Susan , Mou, Eric , Savage, Kerry J. , Zinzani, Pier Luigi , Maurer, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | December 10, 2022 | Volume: 41 | Issue: 11 | Pages: 2076-2086

10.1200/jco.22.02473 | PMID 36495588 Get It

PURPOSE The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients. Harnessing multisource individual patient data from the Hodgkin Lymphoma International Study for Individual Care consortium, we developed and validated a modern clinical prediction model. METHODS Model development via Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines was performed on 4,022 patients with newly diagnosed advanced-stage adult cHL from eight international phase III clinical trials, conducted from 1996 to 2014. External validation was performed on 1,431 contemporaneously treated patients from four real-world cHL registries. To consider association over a full range of continuous variables, we evaluated piecewise linear splines for potential nonlinear relationships. Five-year progression-free survival (PFS) and overall survival (OS) were estimated using Cox proportional hazard models. RESULTS The median age in the development cohort was 33 (18-65) years; nodular sclerosis was the most common histology. Kaplan-Meier estimators were 0.77 for 5-year PFS and 0.92 for 5-year OS. Significant predictor variables included age, sex, stage, bulk, absolute lymphocyte count, hemoglobin, and albumin, with slight variation for PFS versus OS. Moreover, age and absolute lymphocyte count yielded nonlinear relationships with outcomes. Optimism-corrected c-statistics in the development model for 5-year PFS and OS were 0.590 and 0.720, respectively. There was good discrimination and calibration in external validation and consistent performance in internal-external validation. Compared with the IPS, there was superior discrimination for OS and enhanced calibration for PFS and OS. CONCLUSION We rigorously developed and externally validated a clinical prediction model in > 5,000 patients with advanced-stage cHL. Furthermore, we identified several novel nonlinear relationships and improved the prediction of patient outcomes. An online calculator was created for individualized point-of-care use.
Analysis of Negative Reviews of Orthopedic Oncology Surgeons: An Investigation of Reviews from Healthgrades, Vitals, and Google
Qubain, Leeann , Richman, Evan H. , Eaton, Vincent, Brinkman, Joseph C. , Goulding, Krista M, Goulding, Krista

Mayo Clinic

Sarcoma | December 10, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-9

10.1155/2022/4351427 | PMID 36536691 Get It

Background. Physician review websites (PRWs) are increasing in usage and popularity. Our purpose is to characterize one-star reviews of orthopedic oncology surgeons to understand factors in healthcare that contribute to patient satisfaction. Methods. Orthopedic oncology surgeons were randomly selected from the Musculoskeletal Tumor Society. A search for one-star reviews was performed on Google Reviews, Healthgrades, and Vitals.com. Reviews were classified as clinical or nonclinical. Statistical analyses were performed regarding the frequency of reviews and complaints for each category. Results. Of the 7,733 reviews discovered, 908 (11.7%) were identified as one-star reviews. Of 907 usable complaints, 362 (40.8%) were clinical and 545 (59.2%) were nonclinical. The most common nonclinical complaints included bedside manner (65%) and limited time with providers (19%). The most common clinical complaints included complications (26%) and disagreements with the treatment plan (26%). There were 120 surgical and 221 nonsurgical reviews. Surgical patients had a higher rate of clinical complaints. Nonsurgical patients had a higher rate of total complaints. Conclusion. To the best of our knowledge, this is the first study examining PRWs regarding orthopedic oncology surgeons. Most one-star reviews were due to nonclinical complaints from nonsurgical patients. The most common factors are bedside manner, limited time with provider, phone communication issues, and rude/unprofessional conduct.
Emerging point‐of‐care autologous cellular therapy using adipose‐derived stromal vascular fraction for neurodegenerative diseases
Al‐kharboosh, Rawan , Perera, Jonathan , Bechtle, Alexandra , Bu, Guojun , Quiñones‐Hinojosa, Alfredo , Perera, Jonathan Jude , Bu, Guojun

Mayo Clinic

Clinical and Translational Medicine | December 10, 2022 | Volume: 12 | Issue: 12 | Pages: No page available

10.1002/ctm2.1093 | PMID 36495120 Get It

AbstractNeurodegenerative disorders are characterized by the gradual decline and irreversible loss of cognitive functions and CNS structures. As therapeutic recourse stagnates, neurodegenerative diseases will cost over a trillion dollars by 2050. A dearth of preventive and regenerative measures to hinder regression and enhance recovery has forced patients to settle for traditional therapeutics designed to manage symptoms, leaving little hope for a cure. In the last decade, pre‐clinical animal models and clinical investigations in humans have demonstrated the safety and promise of an emerging cellular product from subcutaneous fat. The adipose‐derived stromal vascular fraction (SVF) is an early intervention and late‐stage novel ‘at point’ of care cellular treatment, demonstrating improvements in clinical applications for Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease. SVF is a heterogeneous fraction of cells forming a robust cellular ecosystem and serving as a novel and valuable source of point‐of‐care autologous cell therapy, providing an easy‐to‐access population that we hypothesize can mediate repair through ‘bi‐directional’ communication in response to pathological cues. We provide the first comprehensive review of all pre‐clinical and clinical findings available to date and highlight major challenges and future directions. There is a greater medical and economic urgency to innovate and develop novel cellular therapy solutions that enable the repair and regeneration of neuronal tissue that has undergone irreversible and permanent damage.
Somatic genomic mosaicism in the brain during aging: Scratching the surface
Bae, Taejeong , Abyzov, Alexej , Abyzov, Alexej , Bae, Taejeong , Wang, Yifan , Vaccarino, Flora M.

Mayo Clinic

Clinical and Translational Medicine | December 10, 2022 | Volume: 12 | Issue: 12 | Pages: No page available

10.1002/ctm2.1138 | PMID 36495113 Get It

Progressive brain atrophy and severe neurodevelopmental phenotype in siblings with biallelic COASY variants
Rosati, Justin , Johnson, Jessica, Stander, Zinandré, White, Amy , Tortorelli, Silvia , Bailey, Diana, Fong, Chin‐To, Lee, Bo Hoon , White, Amy L , Lee, Bo Hoon

Mayo Clinic

American Journal of Medical Genetics Part A | December 10, 2022 | Volume: 191 | Issue: 3 | Pages: 842-845

10.1002/ajmg.a.63076 | PMID 36495139 Get It

Abstract Biallelic pathogenic variants in the COASY gene have been associated with two distinct disease phenotypes, that is, COASY ‐protein associated neurodegeneration (CoPAN) and pontocerebellar hypoplasia type 12 (PCH 12). We present two siblings that independently presented with significant hypotonia and respiratory insufficiency at birth. Comprehensive genetic testing revealed homozygous variants within COASY , however, the progressive clinical and neuroradiologic findings described here are unique and have not been described previously. Magnetic resonance imaging showed progressive diffuse parenchymal loss throughout the bilateral cerebral hemispheres and atrophy of the basal ganglia and brainstem. As such, this article brings forth two additional cases of COASY ‐related disorder with abnormal newborn screening acylcarnitine profiles resembling carnitine palmitoyl transferase 1a (CPT1a) deficiency in two siblings who presented at birth with contractures, marked hypotonia and absent respiratory drive.
Optimal assessment of quality of life for patients with prostate cancer
Briggs, Logan , Sentana‐Lledo, Daniel , Lage, Daniel E. , Briggs, Logan G , Trinh, Quoc‐Dien , Morgans, Alicia K.

Mayo Clinic

Therapeutic Advances in Medical Oncology | December 10, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/17588359221141306 | PMID 36531831 Get It

The burden of cancer and oncologic treatment is reflected not only through morbidity and mortality, but also through impacts on patient quality of life (QoL). However, QoL has not been historically measured or addressed with the same rigorous methodology as traditional disease-related outcomes such as overall survival and progression, as these are driven by objective measurements and events. Prostate cancer (PCa) is one of the most prevalent non-cutaneous cancers in men around the world. Both the cancer and its treatment significantly impact patients’ physical, emotional, sexual, social, and overall QoL. Ensuring assessment and integration of QoL in research and clinical care enables improvement in treatment outcomes that matter most to patients while also facilitating alignment of healthcare priorities with reimbursements. Great strides toward this end have been made over the last decade, but significant room for improvement remains. To ensure high quality, reliable data collection, QoL assessment tools must be psychometrically validated, standardized, widely implemented across trials, and regularly assessed to allow internal and external validity, longitudinal comparative effectiveness research, and quality control. Additional consideration should be taken for instruments used to measure the aspects of QoL specific to minority, caregiver, and elderly populations. Open clinical questions include how providers should weight changes in different QoL subscales and how clinically meaningful difference thresholds should be defined. Review of ongoing clinical trials encouragingly reveals an increased focus on measuring and improving QoL for men with PCa which will inform the way we utilize QoL assessments. However, additional efforts herein described are needed to fully optimize these processes. In summary, this review will explain the rationale for QoL assessments in PCa populations, discuss requirements for effective implementation, describe considerations for vulnerable and under-evaluated populations, and summarize ongoing clinical trials assessing patient QoL.
Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis
Zhu, Wen , Zheng, Yongwei , Yu, Mei , Wu, Ya‐Ling , Wei, Jianhui, Fu, Guoping, Schneider, Nicholas O. , Jones, Curtis G., Irani, Mehraboon S. , Padmanabhan, Anand , Aster, Richard H. , Wang, Demin , Wen, Renren , Zhou, Lu , Schneider, Nicholas , Padmanabhan, Anand , Wang, Demin , Wen, Renren , Yu, Mei, Wu, Yaling, Lü, Zhou , Zhou, Lu

Mayo Clinic

Blood | December 9, 2022 | Volume: 141 | Issue: 9 | Pages: 1060-1069

10.1182/blood.2022017612 | PMID 36493339 Get It

AbstractHeparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction characterized by antibodies that recognize platelet factor 4/heparin complexes (PF4/H) and activate platelets to create a prothrombotic state. Although a high percentage of heparin-treated patients produce antibodies to PF4/H, only a subset also makes antibodies that are platelet activating (PA). A close correlation between PA antibodies and the likelihood of experiencing HIT has been demonstrated in clinical studies, but how PA (presumptively pathogenic) and nonactivating (NA) (presumptively benign) antibodies differ from each other at the molecular level is unknown. To address this issue, we cloned 7 PA and 47 NA PF4/H-binding antibodies from 6 patients with HIT and characterized their structural and functional properties. Findings showed that PA clones differed significantly from NA clones in possessing 1 of 2 heavy chain complementarity-determining region 3 (HCDR3) motifs, RX1-2R/KX1-2R/H (RKH) and YYYYY (Y5), in an unusually long complementarity-determining region 3 (≥20 residues). Mutagenic studies showed that modification of either motif in PA clones reduced or abolished their PA activity and that appropriate amino acid substitutions in HCDR3 of NA clones can cause them to become PA. Repertoire sequencing showed that the frequency of peripheral blood IgG+ B cells possessing RKH or Y5 was significantly higher in patients with HIT than in patients without HIT given heparin, indicating expansion of B cells possessing RKH or Y5 in HIT. These findings imply that antibodies possessing RKH or Y5 are relevant to HIT pathogenesis and suggest new approaches to diagnosis and treatment of this condition.
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Francis, Prudence A. , Fleming, Gini F. , Láng, István, Ciruelos, Eva , Bonnefoi, Hervé , Bellet, Meritxell , Bernardo, Antônio , Climent, Miguel Ángel, Martino, Silvana, Bermejo, Begoña , Burstein, Harold J. , Davidson, Nancy E. , Walley, Barbara , Coleman, Robert E. , Müller, Bettina , Du, Fanny Le , Loibl, Sibylle , Ruepp, Barbara , Loi, Sherene , Coates, Alan S. , Gelber, Richard D. , Goldhirsch, Aron, Regan, Meredith M. , Ciruelos, Eva M , Bonnefoi, Hervé R , Walley, Barbara A , Ingle, J , Coleman, Robert E , Müller, Bettina , Le Du, Fanny , Loibl, Sibylle , Winer, Eric , Loi, Sherene , Colleoni, Marco , Coates, Alan S , Gelber, Richard D , Regan, Meredith M , Fleming, Gini , Francis, Prudence A , Geyer, Charles E. , Ingle, James N. , Winer, Eric P. , Colleoni, Marco

Mayo Clinic

Journal of Clinical Oncology | December 9, 2022 | Volume: 41 | Issue: 7 | Pages: 1370-1375

10.1200/jco.22.01065 | PMID 36493334 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690 ) randomly assigned premenopausal women with hormone receptor–positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS versus tamoxifen was a secondary objective. After 8 years, SOFT reported a significant reduction in recurrence and improved overall survival (OS) with adjuvant tamoxifen plus OFS versus tamoxifen alone. Here, we report outcomes after median follow-up of 12 years. DFS remained significantly improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.82; 95% CI, 0.69 to 0.98) with a 12-year DFS of 71.9% with tamoxifen, 76.1% with tamoxifen plus OFS, and 79.0% with exemestane plus OFS. OS was improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.78; 95% CI, 0.60 to 1.01) and was 86.8% with tamoxifen, 89.0% with tamoxifen plus OFS, and 89.4% with exemestane plus OFS at 12 years. Among those who received prior chemotherapy for human epidermal growth factor receptor-2–negative tumors, OS was 78.8% with tamoxifen, 81.1% with tamoxifen plus OFS, and 84.4% with exemestane plus OFS. In conclusion, after 12 years, there remains a benefit from including OFS in adjuvant endocrine therapy, with an absolute improvement in OS more apparent with higher baseline risk of recurrence. [Media: see text]